MAP
ABVX

Moody Aldrich Partners’s Abivax ABVX Stock Holding History

Moody Aldrich Partners’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$222K Sell
1,667
-591
-26% -$66.9K 0.04% 171
2026
Q1 		$251K Sell
2,258
-821
-27% -$97.2K 0.05% 174
2025
Q4 		$415K Buy
3,079
+641
+26% +$69.9K 0.08% 141
2025
Q3 		$207K Buy
+2,438
New +$149K 0.04% 188

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Moody Aldrich Partners's ABVX Position: Q2 2026 in Review

Moody Aldrich Partners reduced its Abivax (ABVX) stake by 26% in Q2 2026, selling an estimated $66.9K and leaving 1,667 shares worth $222K. The position accounts for 0.04% of the portfolio, ranked #171.

Moody Aldrich Partners first reported a position in ABVX in Q3 2025 and has held it in 4 quarters since. The position peaked at $415K in Q4 2025. 302 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • Moody Aldrich Partners held 1,667 shares of Abivax worth $222K as of Q2 2026.
  • Moody Aldrich Partners sold 591 Abivax shares in Q2 2026, an estimated $66.9K.
  • Abivax made up 0.04% of Moody Aldrich Partners's portfolio in Q2 2026, its #171 holding.
  • Moody Aldrich Partners first reported a position in Abivax in Q3 2025 and has held it in 4 quarters since.
  • Moody Aldrich Partners's Abivax position peaked at $415K in Q4 2025.
  • 302 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on Moody Aldrich Partners's 13F filing for Q2 2026, filed 15 Jul 2026.